2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

1

Plasma levels of soluble ACE2 are associated with sex, Metabolic Syndrome, and its biomarkers in a large cohort, pointing to a possible mechanism for increased severity in COVID-19 Sergey A. Kornilov<sup>a\*</sup>, Isabelle Lucas<sup>a</sup>, Kathleen Jade<sup>a</sup>, Chengzhen L. Dai<sup>a</sup>, Jennifer C. Lovejoy<sup>a</sup>, & Andrew T. Magis<sup>a</sup> <sup>a</sup> Institute for Systems Biology, Seattle, WA 401 Terry Ave N Seattle WA 98109-5263 \*Corresponding author; sergey.kornilov@isbcience.org Abstract We examined the associations between plasma concentrations of soluble ACE2 and biomarkers of Metabolic Syndrome in a large (N=2,051) sample of individuals who participated in a commercial wellness program and who underwent deep molecular phenotyping, sACE2 levels were significantly higher in men, compared to women, and in individuals with Metabolic Syndrome, compared to controls. sACE2 levels showed reliable associations with all individuals components of Metabolic Syndrome, including obesity, hypertension, insulin resistance, hyperlipidemia, and as well as markers of liver damage. This profile of associations was statistically significantly stronger in men, compared to women, and points to preexisting cardiometabolic conditions as possible risk factors for increased severity of symptoms in some COVID-19 patients through increased expression of ACE2 in the liver. Keywords: ACE2, SARS-CoV-2, COVID-19, Metabolic Syndrome, GGT, liver function

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

2

List of abbreviations sACE2/mACE2 – soluble/membrane-bound angiotensin-converting enzyme-2 MetS – Metabolic Syndrome GGT – gamma-glutamyl-transferase BMI - Body Mass Index HbA1c – glycohemoglobin A1c HOMA-IR – homeostatic model assessment of insulin resistance hs-CRP – high-sensitivity C-reactive protein Patients who are at high risk for mortality from COVID-19, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are more likely to be older and male, and to have chronic diseases such as hypertension, diabetes, cardiovascular, and chronic lung disease [1,2]. Although the mechanisms behind these associations are poorly understood, this increased risk could be partly associated with increased expression of the cellular receptor of SARS-CoV-2, angiotensin-converting enzyme-2 (ACE2), which is found at elevated levels in older individuals, men, and in cardiovascular and inflammatory conditions [3,4]. ACE2 maintains homeostasis of the renin-angiotensin system and converts angiotensin II to angiotensin 1-7, which has vasodilatory and anti-inflammatory properties. It occurs in a membrane bound form (mACE2), highly expressed in heart, airways, kidney, and liver tissue, and in an enzymatically active soluble form (sACE2) that is generated in response to inflammatory signals and disease via mACE2 shedding into the blood where it normally is found at low levels in healthy individuals. We interrogated the associations between plasma concentrations of sACE2 and biomarkers of Metabolic Syndrome (Body Mass Index, BMI; blood pressure; glycemic markers, and lipid

levels), adiposity (plasma leptin and serum adiponectin), inflammation (high-sensitivity C-reactive protein, hsCRP, white cell count, and interleukin-8) and liver damage (alanine aminotransferase, aspartate transaminase, and gamma-glutamyl-transferase, GGT) in data from a large cohort of participants in a commercial wellness program who had undergone comprehensive multi-omic profiling (N=2,051; 1,238 women and 813 men, aged 22 to 87 years, M=47.3, SD=11.71) (see [5] for details). Clinical laboratory tests were performed in CLIA-certified laboratories by Quest Diagnostics or LabCorp. Plasma sACE2 and leptin levels were measured via proximity extension immunoassaying using Olink® Cardiovascular II proteomics panel. Analyses were performed using transformed and scaled biomarker values in a robust linear regression framework while controlling for age, sex (except sex-specific analyses), eight genetic principal components, smoking, vendor, season, and use of diabetes, cholesterollowering, and ACE-inhibitor medications.

Confirming results from recent studies [3,4], we found higher plasma sACE2 levels in men compared to women ( $P=2x10^{-16}$ ), and in older individuals ( $P=8.6x10^{-11}$ ), with the age association more pronounced in women (for the interaction,  $P_{int}=0.02$ ). We found higher levels of sACE2 in post-menopausal women, compared to pre-menopausal women (P=0.02; see Figure 1).

Individuals who met World Health Organization's (WHO) diagnostic criteria for MetS (N=171) displayed elevated plasma sACE2 levels compared to controls (N=1,880; P=4.7x10<sup>-5</sup>), and the effect was stronger in men (P<sub>int</sub>=8.9x10<sup>-5</sup>). We found all of MetS component biomarkers to be positively associated with plasma sACE2 (see Figure 2). The associations were significantly stronger in men for biomarkers of obesity and adiposity (BMI, P<sub>int</sub>=0.0123; leptin, P<sub>int</sub>=0.0342), insulin resistance and hyperglycemia (HbA1c, P<sub>int</sub>=0.0368; HOMA-IR, P<sub>int</sub>=0.042), as well as triglycerides (P<sub>int</sub>=0.0134) and serum hsCRP (P<sub>int</sub>=0.041). Among examined biomarkers, we found the strongest association between sACE2 and GGT (P=3.44x10<sup>-90</sup>), an enzyme that is an

GGT and sACE2 was also preferentially stronger in men (P=0.01).

The observed robust pattern of associations between increased plasma sACE and MetS points to the possible shared pathways in cardiometabolic disease and COVID-19, implicating insulin resistance, chronic inflammation, and liver damage. This pattern is intriguing given that both sACE2 and mACE2 have been shown to be upregulated in a rat model of chronic liver disease [6] and that sACE2 levels are higher in patients with heart failure [4]. This upregulation may be related to the tissue-specific patterns of increased SARS-CoV-2 infectivity in patients with cardiovascular disease and/or liver damage, and warrants further research on sACE2 as a potential biomarker for COVID-19 severity.




Figure 1. The associations of plasma sACE2 levels with sex, age, and Metabolic Syndrome. Panel A: sex differences in plasma sACE2 levels. Panel B: differences in sACE2

levels between pre- (N=272) and post-menopausal women (N=251) women over 35 years of age. Panel C: associations between sACE2 and age. Panel D: differences in sACE2 levels in individuals who do vs. do not meet diagnostic criteria for MetS and it subcomponents. The following diagnostic criteria, based on WHO guidelines, were used: Obesity: BMI>30 kg/m², Hyperglycemia: fasting glucose >100 mg/dl or other evidence of insulin resistance (e.g., prescription); Hypertension: systolic/diastolic blood pressure >=140/90 mm/hg; Dyslipidemia: triglycerides > 150 or HDL-C <35 for men and <39 for women. Overall status was determined as MetS if the individual met criteria for insulin resistance and satisfied at least one other domain criterion for the syndrome. sACE2: soluble ACE2 (adjusted for covariates and scaled).




Figure 2. Associations between sACE2 and biomarkers of Metabolic Syndrome, inflammation, and liver damage. Panel A: effect size estimates from robust linear regressions predicting sACE2 from biomarkers estimated for men and women separately. Effect sizes are in NPX (log2 metric for the sACE2 measurement) per each standard deviation increase in transformed biomarker. Biomarkers for which a significant interaction with sex was established are marked with \*. Panel B: partial Spearman correlations between study biomarkers and sACE2 levels in the total sample. Panel C: scatterplot of associations between GGT and sACE2. BMI: Body Mass Index; MAP – Mean Arterial Blood Pressure, HbA1c – glycohemoglobin A1c, HOMA-IR – homeostatic model assessment of insulin resistance, HDL-C

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

6

- high-density lipoprotein cholesterol, LDL-C - low-density lipoprotein cholesterol, IL-8 interleukin 8, hsCRP - high-sensitivity C-reactive protein, ALAT - alanine aminotransferase, ASAT – aspartate transaminase, GGT – gamma-glutamyl-transferase. **Declarations** Ethics approval and consent to participate All research was conducted in accordance to regulations and guidelines for observational research in human subjects. The study was reviewed and approved by the Western IRB (Study Number 1178906). The research was performed entirely using de-identified and aggregated data of individuals who had signed a research authorization allowing the use of their anonymized data in research. Per current U.S. regulations for use of deidentified data, informed consent was not required. Consent for publication Not applicable. Availability of data and materials The dataset supporting the conclusions of this article is available from the authors upon request. **Competing interests** The authors were previously employed by Arivale, Inc., and held stock options in the company. Arivale is now closed. Funding

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

7

biliary fibrosis. Journ of Hepatol. 2007;47(3):387-395